Compare EHang Holdings Ltd - ADR (EH) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Repligen Corporation Common Stock — how do they compare? EHang Holdings Ltd - ADR trades at $3.77 (market cap $289.73M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 38.4× EHang Holdings Ltd - ADR's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 47 Days and Repligen Corporation Common Stock for 0 Days on average.
| EH | RGEN | |
|---|---|---|
Market Cap | $289.73M | $11.14B |
Volume | 749,255 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $18.94 | $194.57 |
52-Week Low | $3.78 | $102.87 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $241.33M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $3.78, down 4.79% on the day, reflecting a bearish technical trend. The company reported revenue of $418 million for 2025 but posted a net loss of $276 million, with negative profit margins and ROE. Recent news includes a law firm investigation into investor claims and expansion of its Global Fast Track Program to Vietnam. Cash flow from operations turned positive in 2024 at $158 million, but investing activities remain heavily negative due to capital expenditures.
The outlook is highly speculative, with significant execution and regulatory risks. Investment opportunity hinges on successful commercialization of eVTOL technology, but persistent losses and bearish analyst sentiment suggest caution. Key risks include ongoing legal scrutiny, intense competition, and reliance on future regulatory approvals for growth.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
